IMCV - ETF AI Analysis
Top Page
iShares Morningstar Mid-Cap ETF (IMCV)
IMCV, the iShares Morningstar Mid-Cap ETF, earns a solid overall rating thanks to several strong core holdings like EOG Resources, Elevance Health, US Bancorp, and Phillips 66, which combine solid financial performance, attractive valuations, and generally positive business outlooks. These strengths are partly offset by weaker names such as 3M and Mondelez, where leverage, profitability pressures, and bearish trends introduce caution. A key risk factor is the fund’s meaningful exposure to cyclical sectors like energy and financials, which can make performance more sensitive to economic and market swings.
IMCV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.27B
- Region
- North America
- Expense Ratio
- 0.06%
- Beta
- 0.63
- Issuer
- iShares
- Inception Date
- Jun 28, 2004
- Dividend Yield
- 1.87%
- Asset Class
- Equity
- Index Tracked
- Morningstar US Mid Cap Broad Value Index
IMCV Summary
IMCV is the iShares Morningstar Mid-Cap ETF, which follows the Morningstar US Mid Cap Broad Value Index. It focuses on medium-sized U.S. companies that appear undervalued, aiming to give investors exposure to solid businesses at reasonable prices. The fund spreads money across many sectors, including financials, energy, health care, and technology. Well-known holdings include Automatic Data Processing (ADP), Valero Energy, and 3M. Someone might invest for diversification and the potential long-term growth of mid-sized value companies. A key risk is that these stocks can rise or fall with the overall stock market, and value stocks can stay out of favor for long periods.
How much will it cost me?
This ETF has an expense ratio of 0.06%, which means you’ll pay about $0.60 per year for every $1,000 invested. That’s lower than average because it’s a passively managed fund that tracks an index instead of paying managers to pick individual stocks.
What would affect this ETF?
IMCV could benefit if the U.S. economy grows steadily and value-style mid-cap stocks come back into favor, especially with its exposure to financials, energy, and health care companies like Valero, Phillips 66, and Elevance Health. On the downside, rising interest rates, weaker economic conditions, or tighter regulations on banks, energy, or health care could hurt these sectors and weigh on the ETF’s future performance.
IMCV Top 10 Holdings
IMCV leans heavily into U.S. value names, with a clear tilt toward financials and energy. Refiners like Valero and Phillips 66 have been key engines for the fund, riding strong, steady momentum that’s helped lift overall returns. EOG Resources adds more fuel to the energy story, with rising performance reinforcing that theme. On the financial side, US Bancorp and PNC have been more mixed, occasionally losing steam and tempering gains. Health care exposure through Elevance and Regeneron provides a steadier counterweight, keeping this mid-cap value portfolio balanced but still clearly U.S.-centric.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ADP | Automatic Data Processing | 1.68% | $21.15M | $121.25B | 20.21% | 70Outperform |
 VLO | Valero Energy | 1.39% | $17.47M | $97.95B | 96.84% | 69Neutral |
 PSX | Phillips 66 | 1.37% | $17.19M | $96.36B | 77.80% | 73Outperform |
 MMM | 3M | 1.33% | $16.77M | $97.03B | 13.00% | 59Neutral |
 USB | US Bancorp | 1.29% | $16.23M | $93.10B | 26.89% | 76Outperform |
 ELV | Elevance Health | 1.24% | $15.64M | $93.34B | 35.36% | 76Outperform |
 PNC | PNC Financial | 1.25% | $15.76M | $89.97B | 23.21% | 71Outperform |
 REGN | Regeneron | 1.24% | $15.66M | $93.39B | 39.80% | 78Outperform |
 MRNA | Moderna | 1.26% | $15.80M | $96.40B | 944.76% | 59Neutral |
 MDLZ | Mondelez International | 1.18% | $14.80M | $84.58B | 17.49% | 62Neutral |
IMCV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IMCV, the sentiment is Positive. The current price of 97.72 is above the 20-day moving average (MA) of 97.61, above the 50-day MA of 95.76, and above the 200-day MA of 90.84, indicating a bullish trend. The MACD of 1.09 indicates Negative momentum. The RSI at 52.73 is Neutral, neither overbought nor oversold. The STOCH value of 47.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMCV.
IMCV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IMCV | $97.72 | $103.00(5.40% Upside) | $1.27B | 0.06% | 69Neutral |
 IJJ | $143.37 | $171.50(19.62% Upside) | $8.61B | 0.18% | 70Neutral |
 FMDE | $40.72 | $49.06(20.49% Upside) | $8.58B | 0.23% | 69Neutral |
 XMMO | $129.57 | $183.72(41.79% Upside) | $5.98B | 0.34% | 71Outperform |
 MDYV | $92.17 | $110.12(19.47% Upside) | $2.78B | 0.15% | 70Neutral |
 IVOV | $111.33 | $133.80(20.18% Upside) | $1.24B | 0.10% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IMCV | iShares Morningstar Mid-Cap ETF | 97.72 | 18.93 | 24.03% | |
| IJJ | iShares S&P Mid-Cap 400 Value ETF | 143.37 | 16.80 | 13.27% | |
| FMDE | Fidelity Enhanced Mid Cap ETF | 40.72 | 5.17 | 14.56% | |
| XMMO | Invesco S&P MidCap Momentum ETF | 129.57 | -7.22 | -5.28% | |
| MDYV | SPDR S&P 400 Mid Cap Value ETF | 92.17 | 10.88 | 13.38% | |
| IVOV | Vanguard S&P Mid-Cap 400 Value ETF | 111.33 | 13.11 | 13.35% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.